Literature DB >> 16344614

Large-vessel involvement in giant cell arteritis.

Tim Bongartz1, Eric L Matteson.   

Abstract

PURPOSE OF REVIEW: Large-vessel involvement in giant cell arteritis occurs in over a quarter of patients with this disease. Stenosis of the primary and secondary branches of the aorta may cause claudication and tissue gangrene, whereas aortitis may lead to aneurysm formation and dissection, often many years after the initial diagnosis. RECENT
FINDINGS: Subsets of giant cell arteritis are probably caused by variations in the pathobiology of the disease. Radiographic imaging with some form of angiography is essential to reach a proper diagnosis. Although survival in giant cell arteritis is generally good, subsets of patients with aneurysm formation have a markedly diminished life expectancy. Glucocorticosteroids continue to be the mainstay of treatment for giant cell arteritis and its complications.
SUMMARY: Advances in diagnostic techniques including proteomic and genomic approaches should improve our understanding of the pathogenesis as well as the assessment of disease activity and extent. We provide a suggested algorithm for the evaluation of patients with large-vessel disease in giant cell arteritis.

Entities:  

Mesh:

Year:  2006        PMID: 16344614     DOI: 10.1097/01.bor.0000197996.04709.4e

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  33 in total

1.  Clinical course and management of a consecutive series of patients with "healed temporal arteritis".

Authors:  Yvonne C Lee; Robert F Padera; Erika H Noss; Anne H Fossel; Don Bienfang; Matthew H Liang; William P Docken
Journal:  J Rheumatol       Date:  2011-12-01       Impact factor: 4.666

2.  Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study.

Authors:  G A Hooisma; H Balink; P M Houtman; R H J A Slart; K D F Lensen
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

Review 3.  [Imaging diagnostics of large vessel vasculitis].

Authors:  M Czihal; S Förster; U Hoffmann
Journal:  Radiologe       Date:  2010-10       Impact factor: 0.635

Review 4.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Towards an optimal semiquantitative approach in giant cell arteritis: an (18)F-FDG PET/CT case-control study.

Authors:  Florent L Besson; Hubert de Boysson; Jean-Jacques Parienti; Gérard Bouvard; Boris Bienvenu; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-06       Impact factor: 9.236

Review 6.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 7.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Giant cell arteritis as a cardiovascular entity.

Authors:  P Houthuizen; P E Polak; M A L Edelbroek; C H Peels
Journal:  Neth Heart J       Date:  2009-08       Impact factor: 2.380

9.  [A 79-year-old man with B symptoms and jaw claudication].

Authors:  S Krug; I Portig; D Librizzi; A Pfestroff; T Gress; P Michl
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

10.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.